TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06121219

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Training in the Blind Field
Description: A computer software and chin-rest necessary to perform visual training will be loaned to each subject to be used at home. Subjects will perform one to two daily training sessions in their home, consisting of 200-300 trials each. The visual task performed repetitively will involve discriminating the direction of motion, the presence of motion, or the orientation of a visual stimulus (either a small cloud of dots or bars) located at a predetermined location in the blind field. The computer program will automatically create a record of patient performance during each home training session. Subjects will train daily (about 40-60 minutes total), 5 to 7 days per week for at least 3 and up to 12 months at a time.
Study: NCT06085703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Henagliflozin
Description: Henagliflozin will be initiated and maintained at 5mg/day every morning. If necessary, the dose can be increased to 10mg once daily. All patients will also continue on their existing dose and regimen of metformin throughout the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gliclazide
Description: Gliclazide will be initiated and maintained at 30mg/day every morning. If necessary, the dose can be increased to 120mg once daily. All patients will also continue on their existing dose and regimen of metformin throughout the study.
Study: NCT06406725

Intervention type: DIAGNOSTIC_TEST
Intervention: Point-of-Care Ultrasound of the Airway
Description: Patients who are recruited will have an ultrasound performed of their larynx while they are on noninvasive positive pressure ventilation and then a second ultrasound when they are removed from noninvasive positive pressure ventilation. Between the two ultrasounds, the otolaryngology team will perform their fiberoptic nasolaryngoscopy, as per standard unit protocol and patient care.
Study: NCT05356481

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: segmental muscle vibration
Description: Segmental muscle vibration will delivered over the target muscles by means of vibrator with general physical therapy session

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: segmental muscle vibration
Description: Segmental muscle vibration will delivered over the target muscles by means of vibrator with general physical therapy session
Study: NCT05644392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab Injection
Description: Cadonilimab Injection, 6mg/kg, intravenous drip ,q2w,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Regorafenib 80mg, po, orally once daily
Study: NCT06566365

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Subcostal Transversus Abdominis Plane Block
Description: After ensuring airway safety under general anesthesia, a bilateral Transversus Abdominis Plane Block using 20 cc of 0.25% bupivacaine with a subcostal approach under ultrasound guidance will be administered

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Subcostal Transversus Abdominis Plane Block
Description: After ensuring airway safety under general anesthesia, a bilateral Transversus Abdominis Plane Block using 20 cc of 0.25% bupivacaine with a subcostal approach under ultrasound guidance will be administered
Study: NCT05977179

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention to mitigate Post-Acute COVID-19 Syndrome
Description: As it was described in the arm/group descriptions.

Intervention type: OTHER
Group type: OTHER
Intervention: Attention Control
Description: As it was described in the arm/group descriptions.
Study: NCT06582771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib
Description: Sotorasib 960 mg (8 pills) daily
Study: NCT05738291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1839100
Description: BI 1839100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1839100
Description: BI 1839100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1839100
Description: BI 1839100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1839100
Description: BI 1839100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1839100
Description: BI 1839100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1839100
Description: BI 1839100

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching BI 1839100
Description: Placebo matching BI 1839100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: midazolam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: digoxin
Description: digoxin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosuvastatin
Description: rosuvastatin
Study: NCT05984667

Intervention type: BEHAVIORAL
Intervention: C-SMART
Description: The C-SMART intervention includes approximately 8 individual therapy sessions, each approximately 60 minutes in length, delivered weekly. C-SMART intervention components include cognitive rehabilitation and mindfulness training.
Study: NCT05638139

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SygeLIX-F + SygeLIX-G
Description: SygeLIX-F (plug) is inserted through the internal orifice while cryptoglandular space is filled by SygeLIX-G (gel).
Study: NCT05087680

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACTPrEP
Description: ACTPrEP will include a 60-minute initial session and a series of 30-minute follow-up sessions. Sessions will focus on the Thoughts, Emotions, Associations, Memories, and Sensations (TEAMS) relevant to PrEP uptake and adherence.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Standard of Care
Description: Enhanced Standard of Care (ESOC) will include one 30-minute PrEP education session.
Study: NCT06064695

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole-body Electrical Muscle Stimulation Exercise
Description: This is a fitness device that delivers whole-body electrical muscle stimulation in conjunction with exercise programs using an iPad App. The stimulation suit (fitted shorts/shirt, vest, leg straps, arm straps) will be donned with the assistance of trained research personnel. Muscle groups stimulated include biceps, triceps, pectorals, abdominals, periscapular musculature, paraspinal musculature, gluteus musculature, quadriceps, and hamstrings. The stimulation level of each individual muscle group can be tailored to participant responses and tolerance (i.e. stimulation of the quadriceps and biceps can occur at different settings). While the participant is following along with the video, a qualified health care professional will be monitoring and adjusting the stimulation levels based on participant responses; rate of perceived exertion will also be monitored to ensure safe moderate intensity levels are maintained.
Study: NCT03767231

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Xpert HCV Viral Load Finger-stick Point-of-Care test (Cepheid)
Description: The investigators will randomly assign eligible and consented patients to either to HCV POC VL Group or Reference Group. All participants will take a short survey regarding HCV care and treatment. As part of the investigators' ED HCV Screening and Linkage to Care Program, all participants will receive the standard-of-care clinical laboratory-based HCV RNA viral load testing via whole blood (i.e. patient will receive blood drawn). This standard-of-care HCV viral load testing result will be provided to participant when it is available (usually 1-2 days later). Participants in the HCV POC VL Group will receive the novel POC HCV RNA viral load testing and the result of the novel test will be disclosed to the patients approximately within 1 to 1½ hours of the testing.
Study: NCT05227430

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational video tutorials
Description: Educational video tutorials (Hysterectomy, Bilateral salpingo-oophorectomy, Bilateral salpingectomy)
Study: NCT05828901

Intervention type: OTHER
Intervention: S1PR analysis on immune cells
Description: S1P receptor 1 and 5 expression will be measured on immune cells

Intervention type: OTHER
Intervention: S1PR analysis on immune cells
Description: S1P receptor 1 and 5 expression will be measured on immune cells
Study: NCT04713007

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality of Life Ted Talks
Description: There will be 9 training modules released weekly on the tablet. A survey will be required at baseline, each of the 9 weeks and at 3 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality of Life Supportive Resources
Description: The tablet will be preloaded with cancer information and supportive care resources from the National Cancer Institute. A survey will be required at baseline, each of the 9 weeks and at 3 months.
Study: NCT06644417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQA3605 tablets plus NAs
Description: TQA3605 tablets is core protein regulator
Study: NCT05637593

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Upper-limb movement training with the aid of RAS
Description: Three target bowls, labeled as the left, middle, and right target bowl, will be placed on the table at an equal distance from the main bowl. The distance between a target bowl and the main bowl is set at 30 cm. Wooden beads with a diameter of 2 cm will be put in target bowls. The main bowl will be placed in front of the patient.~Patients will be asked to listen to the RAS sound, use the right hand to take one bead at a time from the left target bowl to the main bowl, repeat this movement for the middle and right target bowls, and keep repeating this order. They should keep their movements consistent with the sound of the RAS, with one RAS sound corresponding to one pick-up movement.~Each daily training will consist of three rounds separated by two 5-minute breaks. Each round will consist of four consecutive sessions (for each session: 2-minute training followed by a 30-second break). The training will last for a total of 21 days.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Upper-limb movement training without the aid of RAS
Description: Three target bowls, labeled as the left, middle, and right target bowl, will be placed on the table at an equal distance from the main bowl. The distance between a target bowl and the main bowl is set at 30 cm. Wooden beads with a diameter of 2 cm will be put in target bowls. The main bowl will be placed in front of the patient.~Patients will be asked to use the right hand to take one bead at a time from the left target bowl to the main bowl, repeat this movement for the middle and right target bowls, and keep repeating this order. They are asked to execute the task as fast as possible.~Each daily training will consist of three rounds separated by two 5-minute breaks. Each round will consist of four consecutive sessions (for each session: 2-minute training followed by a 30-second break). The training will last for a total of 21 days.
Study: NCT04967430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon Lambda-1A
Description: Peginterferon lambda is a covalent conjugate of human recombinant non-pegylated IFN lambda (IFN L) and a 20-kDa linear PEG chain.~Peginterferon lambda Injection is a sterile, nonpyrogenic, ready-to-use solution (0.4 mg/mL) that is clear to opalescent, colorless to pale yellow, and essentially free of particles. Lambda Injection is provided in a 1-mL long Type I glass syringe (0.18 mg/syringe) with a staked 29-gauge, 1/2- inch, thin-walled needle. The syringe has a rigid needle shield and is stoppered with a plunger stopper. Syringes are prefilled with a solution of Peginterferon lambda Injection, mannitol, L-histidine, polysorbate 80, hydrochloric acid, and water for injection; they are intended for a single use at adjustable doses. The syringe is marked with dose indicator lines, which are used as a reference point for administering the correct dose.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will be 0.9% sodium chloride (normal saline) solution. A plastic 1 mL syringe will be prefilled by the study pharmacy. Each syringe will contain 0.5 mL (0.45 mL to match the volume of the Interferon plus 0.05 mL overfill) to allow for needle priming by the unblinded study nurse.
Study: NCT06408090

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IDECIDE-HOSPICE
Description: 12-pg educational booklet detailing information about hospice including what hospice is, why someone would use hospice, who pays for hospice, and where hospice services are delivered

Intervention type: OTHER
Group type: OTHER
Intervention: IDECIDE-HOSPICE
Description: 12-pg educational booklet detailing information about hospice including what hospice is, why someone would use hospice, who pays for hospice, and where hospice services are delivered
Study: NCT05968950

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thoracic ultrasound
Description: The use of ultrasound to count ribs in order to surface mark the corresponding spinal level
Study: NCT05195879

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: XTR004
Description: Single dose intravenous injection of XTR004. Serial whole-body PET scan will be obtain after injection, blood and urine collection after injection for the assessment of pharmacokinetics.
Study: NCT05187195

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based telerehabilitation with exercise videos
Description: Balance, walking, strengthening, posture videos etc. taken in different positions will be uploaded to the telerehabilitation system. A personalized exercise program will be created from these exercises. This program will be defined to the account of the patient and the follow-up of the person will be carried out through the system.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise brochure
Description: Photos and explanations of exercises taken in different positions such as balance, walking, strengthening, posture etc. will be uploaded to the telerehabilitation system. A personalized exercise brochure will be created from these exercises. This program will be defined for the patient's account and the patient will be asked to follow the exercises with this brochure.
Study: NCT06282887

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music therapy
Description: The intervention has two parts. The first part is an approximately 15-minute music therapy session to induce relaxation and positive memories attached to the relaxing live music provided by a credentialed music therapist. The second part is music listening during the scanning process.
Study: NCT06343714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FB1003
Description: Subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FB1003
Description: Subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FB1003
Description: Subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FB1003
Description: Subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FB1003
Description: Subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FB1003
Description: Subcutaneous (SC) injection
Study: NCT06644417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQA3605 tablets plus NAs
Description: TQA3605 tablets is core protein regulator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TQA3605 Placebo plus NAs
Description: Placebo without drug substance
Study: NCT06343714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FB1003
Description: Subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FB1003
Description: Subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous (SC) injection
Study: NCT05949853

Intervention type: OTHER
Intervention: the respiratory parameters (AHI) and time spent
Description: interpret the recording will be evaluated for PSG, PV and PV+ASEEGA Apnea Hypopnea Index as assessed by PSG (respiratory signals + electro-encephalography + electro-oculography + chin electromyography), PV (respiratory signals) and PV+ASEEGA (respiratory signals + result of sleep stages and arousals scoring by ASEEGA algorithm based on automatic analysis of one EEG Cz-Pz channel)
Study: NCT06627686

Intervention type: DIAGNOSTIC_TEST
Intervention: Air way occlusion pressure
Description: Predictive Value of Airway Occlusion Pressure, Maximal Inspiratory Pressure and Their Ratio for Successful Extubation in Patients with Traumatic Brain Injury
Study: NCT06343714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous (SC) injection
Study: NCT05837923

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Relief Active Study Product 1.1 Usage
Description: Participants will use their Radicle Relief Active Study Product 1.1 as directed for a period of 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Relief Active Study Product 1.2 Usage
Description: Participants will use their Radicle Relief Active Study Product 1.2 as directed for a period of 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control Form 1
Description: Participants will use their Placebo Control Form 1 as directed for a period of 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Relief Active Study Product 2.1 Usage
Description: Participants will use their Radicle Relief Active Study Product 2.1 as directed for a period of 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control Form 2
Description: Participants will use their Placebo Control Form 2 as directed for a period of 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control Form 3
Description: Participants will use their Placebo Control Form 3 as directed for a period of 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Relief Active Study Product 3.1 Usage
Description: Participants will use their Radicle Relief Active Study Product 3.1 as directed for a period of 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Relief Active Study Product 3.2 Usage
Description: Participants will use their Radicle Relief Active Study Product 3.2 as directed for a period of 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Relief Active Study Product 3.3 Usage
Description: Participants will use their Radicle Relief Active Study Product 3.3 as directed for a period of 6 weeks.
Study: NCT05061134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceralasertib
Description: Ceralasertib (240 mg) will be administered orally twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceralasertib
Description: Ceralasertib (240 mg) will be administered orally twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceralasertib
Description: Ceralasertib (240 mg) will be administered orally twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceralasertib
Description: Ceralasertib (240 mg) will be administered orally twice daily.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab (1500 mg) will be administered intravenously once every 28 days for participants who weight above \> 30 kgs. For participants who weigh below ≤ 30 kgs, weight-based dosing equivalent to 20 mg/kg of durvalumab will be administered.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab (1500 mg) will be administered intravenously once every 28 days for participants who weight above \> 30 kgs. For participants who weigh below ≤ 30 kgs, weight-based dosing equivalent to 20 mg/kg of durvalumab will be administered.
Study: NCT06009926

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo urine sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo urine sample collection

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Broccoli Sprout/Broccoli Seed Extract Supplement
Description: Given PO
Study: NCT06331585

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low dose radiotherapy
Description: LDRT (5Gy/5f) of oligometastasis, oligoprogression, and oligopersistence of NSCLC after immunotherapy
Study: NCT06627361

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PRO-FLEX PIVOT Foot evaluation
Description: The subject will wear the PRO-FLEX PIVOT foot for 4 weeks, following which they will complete questionnaires and undergo a Time Up and Go test

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Class III ESAR Foot evaluation
Description: The subject will wear his usual Class III ESAR Foot foot for 4 weeks, following which they will complete questionnaires and undergo a Time Up and Go test
Study: NCT05539157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JCXH-211
Description: JCXH-211 administered once every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JCXH-211
Description: JCXH-211 administered once every 28 days
Study: NCT04706546

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hemodynamic effect of exercise under Sildenafil
Description: Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise under SIldenafil.

Intervention type: OTHER
Group type: OTHER
Intervention: Hemodynamic effect of exercise
Description: Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise.
Study: NCT06009926

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Broccoli Sprout/Broccoli Seed Extract Supplement
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Administration
Description: Given PO